PATENT CLAIM ANALYSIS

Application Number: 16152750
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as pain associated with complex regional pain syndrome.

Claim (Index 17):
The method of  claim 14 , wherein the zoledronic acid is the most potent bisphosphonate administered.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 97.0
- Lexical Diversity: 1.28125
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16110869', '15703891', '15820305', '15782480', '15438513']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8575738305035508
- 35 USC 102 Novelty (BERT): 0.591250039959519
- Combined Prediction Score: 0.8309414514491477
- Mean Citation Score: 639.420738
- Max Citation Score: 645.5725
- Similarity Product: 403.5021290180087

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test